March 1, 1986European Heart Journal
Amiodarone-induced torsades de pointes
Key result
Amiodarone use was associated with marked QTc prolongation and syncope due to torsades de pointes or ventricular fibrillation in five patients.
Why the study?
Does amiodarone cause torsades de pointes or ventricular fibrillation in patients treated for arrhythmias?
Population
5 patients with amiodarone-induced syncope due to torsades de pointes or ventricular fibrillation.
Design
Case_series
Authors
Discussion
Loading...
Member takes
Implication
Amiodarone may rarely trigger TdP/VF via QTc prolongation in vulnerable patients; leaves open incidence and risk-factor questions for prospective study.
Study Design
Type
Case Report (n=5)
Structured PICO
Does amiodarone cause torsades de pointes or ventricular fibrillation in patients treated for arrhythmias?
P
Population
5 cases of patients experiencing amiodarone-induced syncope due to torsades de pointes or ventricular fibrillation.
E
Exposure
Amiodarone
O
Outcome
Syncope due to torsades de pointes or ventricular fibrillationsafety
Amiodarone can induce marked QTc prolongation leading to life-threatening torsades de pointes or ventricular fibrillation, particularly in patients with predisposing factors like hypokalemia or prior drug-induced arrhythmias.
Cite This Study
Brown et al. (1986) conducted a case report in Amiodarone-induced syncope due to torsades de pointes or ventricular fibrillation (n=5). Amiodarone was evaluated on Syncope due to torsades de pointes or ventricular fibrillation. Amiodarone use was associated with marked QTc prolongation and syncope due to torsades de pointes or ventricular fibrillation in five patients.